From: Particle therapy and nanomedicine: state of art and research perspectives
Ion type | E | LET (keV/μm) | Dose rate (Gy/min) | Sample | Radio-enhancer | Data | Evidence of radical effects | Localisation | Refs./year |
---|---|---|---|---|---|---|---|---|---|
Helium | 143 MeV/amu | 2.24 (HIMAC) | 4 | pBr322 plasmid | PtTC complex | SSB/DSB | Yesa | – | Usami et al. (2005) |
Carbon |
276 MeV/amu 109 MeV/amu |
13.4 (HIMAC) 25.6 |
7 6.2 | pBr322 plasmid | PtTC complex | SSB/DSB | Yes | – | Usami et al. (2007) |
Iron |
400 MeV/amu 100 MeV/amu |
200 (HIMAC) 550 | – | pBr322 plasmid | PtTC complex | SSB/DSB | Yes | – | |
Carbon | 290 MeV/amu |
13 (HIMAC) 70 |
7 6.2 | CHO-K-1 cells | PtTC complex | SF | Yes | Yes | Usami et al. (2008a) |
Helium | 150 MeV/amu | 2 & 7 (HIMAC) | 4 | CHO-K-1 cells | PtTC complex | SF | Yes | Yes | |
Carbon | 276 MeV/amu | 13.4 (HIMAC) | 4 | pBr322 plasmid | PtNP-PAA 3 nm | Yes | – | Porcel et al. (2010) | |
Carbon | 290 MeV/amu |
13.2 (HIMAC) 110 | 7 | pBr322 plasmid | PtNP-PAA 3 nm | Yes | – | ||
Protons | 40 MeV |
1 (Pristine peak) 35 (Bragg Peak) | 480 | CT26 cells | AuNPs 2–13 nm | SF | – | – | Kim et al. (2010) |
Protons | 40 MeV |
1 (Pristine peak) 35 (Bragg Peak) | 480 | CT26 cells | FeNPs 14 nm | SF | – | – | |
Protons | 40 MeV |
1 (Pristine peak) 35 (Bragg peak) | – | CT26 T in mice | AuNPs 2–13 nm | T growth/mice survival | – | – | |
Protons | 80 MeV | – | 4 | NSA fibrocarcoma in mice | Cis-Pt | T growth/mice survival | – | Yes | Terakawa et al. (2011) |
Protons | 160 MeV | SOBP | – | DU 145 Prostate carcinoma cells | Phage plus AuNPs 44 nm | SF | – | – | Polf et al. (2011) |
Helium | 150 MeV/amu | 2.3 (HIMAC) | 4 | pBr322 plasmid | PtNP-PAA 3 nm | SSB/DSB | Yes | – | Porcel et al. (2012) |
Carbon | 290 MeV/amu |
13.2 110 (HIMAC) | 7 | pBr322 plasmid | PtNP-PAA 3 nm | SSB/DSB | Yes | – | |
Protons | 45 MeV | Pristine Bragg Peak Entrance plateau | 0.5–0.7 | CT26 T in mice | AuNPs 14 nm | T uptake/T growth/Mice survival | Yes | – | Kim et al. (2012) |
Protons | 45 MeV | Pristine Bragg Peak Entrance plateau | 0.5–0.7 | CT26 T in mice | FeNPs 10.6 nm | T uptake/T growth/Mice survival | Yes | – | |
Carbon | 62 MeV | 290 | HeLa | Glu-AuNPs 6 nm | – | – | Kaur et al. (2013) | ||
Carbon | 270 MeV/amu | 13 (HIMAC) | 7 | pBr322 plasmid | GdBNP 3 nm | SSB/DSB | Yes | – | Porcel et al. (2014) |
Helium | 150 MeV/amu | 2.3 (HIMAC) | 4 | pBr322 plasmid | GdBNP 3 nm | SSB/DSB | – | – | |
Carbon | 270 MeV/amu | 13 | 7 | CHO | GdBNP 3 nm | SF | Yes | ||
Protons | 3 MeV | 12 | – | RT112 | Citrate-AuNPs 50 nm | Yes | Yes | Jeynes et al. (2014) | |
Protons | 2 MeV | 10 and 25 | 1 | A431 | Amine PEG capped AuNPs 5 & 10 nm | SF | Yes | Yes | (Li et al. (2016) |
Carbon | 165 MeV/amu | 70 (HIRFL) | 0.4 | HeLa | AuNPs 14 nm (1.5–15 μg/mL) | Viability, SF, cell cycle | Yes | Yes | Liu et al. (2015, 2016) |
Protons | 150 MeV |
0.44 3.6 | – | pBr322 plasmid | PtNP-PAA 3 nm | SSB/DSB | Yes | – | Schlathölter et al. (2016) |
Protons | 150 MeV |
0.44 3.6 | – | pBr322 plasmid | GdBNP 3 nm | SSB/DSB | Yes | – |